Charts

10 Feb, 2024
09 Feb, 2024

News

16 Nov, 2023
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update.
17 Oct, 2023
Gainers Biocept (NASDAQ:BIOC) shares moved upwards by 109.4% to $1.07 during Tuesday's after-market session. Trading volume for this ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them. The post Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The #1 AI Investment Might Be This Company You’ve Never Heard Of The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a ...
Gainers Assembly Biosciences (NASDAQ:ASMB) shares increased by 108.0% to $1.51 during Tuesday's pre-market session. The company's ...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. ...
16 Oct, 2023
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. (“Healios”) under the acute respiratory distress syndrome (“ARDS”) global license.
11 Oct, 2023
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating ...
Gainers Tempest Therapeutics (NASDAQ:TPST) shares increased by 692.0% to $1.9 during Wednesday's pre-market session. The company's ...
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
10 Oct, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% ...
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares moved upwards by 33.2% to $0.48 during Tuesday's regular session. The current volume ...
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. SMX (Security Matters) Public ...
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to ...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening ...
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the sample size required to achieve statistical significance is considerably larger, Athersys intends to conduct additional data analysis with independent statisticians. The Company plans to pause enrollment of new patients while this analysis is being conducted.
04 Oct, 2023
In this article, we will be taking a look at the 20 foods consumed by longest living people every day. If you are not interested in the details about market insights on longevity, head straight to the 5 Foods Consumed By Longest Living People Every Day. The pursuit of longevity and vitality has captivated humankind […]
03 Oct, 2023
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent). Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies for animals.
02 Oct, 2023
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023. Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys’ Audit Committee and previously serving as Chair of its Nominations, Governance & Compliance Committee.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
28 Sep, 2023
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 110.9% to $0.42 during Thursday's after-market session. At the ...
15 Sep, 2023
Gainers Perspective Therapeutics (AMEX:CATX) stock increased by 35.6% to $0.28 during Friday's after-market session. Trading volume for ...
06 Sep, 2023
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney transplantation. Machine perfusion refers to a technology used for limiting the damaging effects of removing and transporting kidneys prior to transplantation. It involves a machine that pumps fluid around the organ while it is outside the body, allowing for the potential therapeutic treatments to the kidney after donation.
25 Aug, 2023
Unraveling the Valuation and Financial Health of Athersys Inc
18 Aug, 2023
Gainers Assure Hldgs (NASDAQ:IONM) stock rose 62.3% to $0.5 during Friday's regular session. As of 13:30 EST, this security is trading ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Applied Materials (AMAT) stock is climbing higher on Friday after getting new price targets following its latest earnings report. The post AMAT Stock Alert: Analysts Raise Applied Materials Price Targets After Earnings appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The $1 Investment You MUST Take Advantage of Right Now
Gainers Alpha Tau Medical (NASDAQ:DRTS) shares increased by 16.7% to $4.2 during Friday's pre-market session. The company's market cap ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athersys (ATHX) stock is falling on Friday after the biotechnology company announced a $3.5 million public stock offering. The post Why Is Athersys (ATHX) Stock Down 36% Today? appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement It doesn’t matter if you have $500 or $5 million. Do this now. The $1 Investment You MUST Take Advantage of Right Now
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement It doesn’t matter if you have $500 or $5 million. Do this now. The $1 Investment You MUST Take Advantage of Right Now
Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 10,937,500 shares of common stock and Series B Warrants to purchase up to an aggregate of 10,937,500 shares of common stock. The Series A and Series B Warrants will have an exercise price of $0.32 per share, will be exercisable immediately following the date of issuance and will expire in five years and one and a half years, respectively.
16 Aug, 2023
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.
15 Aug, 2023
In this article, we will be taking a look at the 20 states with the longest life expectancy in America. If you want to skip our detailed analysis of companies that are working on improving life expectancy, you can go directly to see the 5 States With The Longest Life Expectancy In America. Life Expectancy […]
11 Aug, 2023
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings.
10 Aug, 2023
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected ...
31 Jul, 2023
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke.
26 Jul, 2023
Gainers Mallinckrodt (AMEX:MNK) stock increased by 60.7% to $0.71 during Wednesday's regular session. Trading volume for Mallinckrodt's ...
06 Jul, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for ...
03 Jul, 2023
Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently ...
01 Jun, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma. This study is being conducted at The University of Texas Health Science Center at Houston (UTHealth Houston) and Memorial Hermann-Texas Medical Center, a leading certified Level One Trauma Center, and approximately 140 patients will be enrolled in cohort three. MATRICS-1 is supported in part by MTEC (Medical Technology Enterprise Consortium) in partnership with the Department of Defense, and funding from Memorial Hermann Foundation.
23 May, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier (“the supplier”). The Company previously entered into agreements with the supplier to assist in the scale-up and manufacturing of clinical and commercial grade MultiStem® using Athersys’ bioreactor production processes.
18 May, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update.
08 May, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be participating in the Pharma Manufacturing World Summit and Allogeneic Cell Therapies Summit, both in Boston, Massachusetts. Dr. Sarah Busch, Vice President of Regenerative Medicine and Head of Business Development, will be attending the American Thoracic Society’s (ATS) Respiratory Innovation Summit in Washington, DC.
01 May, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.
21 Apr, 2023
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.
19 Apr, 2023
Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the “offering”). The warrants have an exercise price of $0.96 per share, are initially exercisable beginning six months following the date of issuance and expire seven years from the initial exercise date.
18 Apr, 2023
Athersys Inc (NASDAQ: ATHX) shares are trading lower by 12.94% to $0.98 Tuesday morning.The company announced a $3.7 million ...
Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the “offering”). The warrants will have an exercise price of $0.96 per share, will be initially exercisable beginning six months following the date of issuance and will expire seven years from the initial exercise date.
10 Apr, 2023
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2.

Related Articles